Author Archives: Patricia Inacio PhD

FDA Asks GSK for More Evidence of Mepolizumab’s Ability to Help Treat Flares in COPD Patients

GlaxoSmithKline’s application for approval of mepolizumab as an add-on therapy to reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) requires more clinical data, the U.S. Food and Drug Administration (FDA) said in a complete response letter. GSK sought approval for mepolizumab as an add-on to inhaled corticosteroid-based maintenance treatments used…

Switch to Electronic Cigarettes May Help COPD Patients, Study Reports

Electronic cigarettes help reduce exacerbations and improve exercise capacity in patients with chronic obstructive pulmonary disease (COPD) who saw their condition get worse by smoking conventional cigarettes, a new study reports. The study, “Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up” was…

FDA Approves Daliresp Dosage as First-line Therapy for Severe COPD

AstraZeneca’s Daliresp (roflumilast) is now approved at 250 micrograms (mcg) for the first four weeks followed by 500 mcg thereafter to treat patients with chronic obstructive pulmonary disease (COPD). This approval by the U.S. Food and Drug Administration (FDA) will help reduce the rate of discontinuation previously reported in patients…

Bellerophon Announces Positive Results for INOpulse Therapy for Pulmonary Hypertension Associated with COPD

INOpulse as a therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) showed promising results in a Phase 2 clinical trial, Bellerophon Therapeutics, the clinical-stage company developing the INOpulse program, announced. INOpulse is a portable nitric oxide delivery system being developed for the treatment of PH-COPD. Nitric oxide…